Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: biostruggle who wrote (984)	5/8/2000 4:46:00 PM
From: Robohogs	Read Replies (1) \| Respond to of 10345

The issue revolves around transactions where ELN gives a partner $50 million (for example) for some portion of a JV. The partner then contributes its IP (intellectual property) and some people plus some or all of ELN's $$$. The JV then pays ELN for doing some research for them, translating ELN expense into net income, or so the bears say. The truth lies somewhere in between I bet. The answer depends on if ELN or the JV or the partner is doing the research. IMHO, I like what they are doing because it increases the odds of hitting many more singles and doubles, something ELN is good at. No blockbusters here (except for maybe Z and Alzheimer's stuff), but a lot of good niche products and royalties from others' blockbusters.